5KZC
| Crystal structure of an HIV-1 gp120 engineered outer domain with a Man9 glycan at position N276, in complex with broadly neutralizing antibody VRC01 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Engineered outer domain of gp120, VRC01 Fab heavy chain, ... | Authors: | Julien, J.-P, Jardine, J.G, Diwanji, D, Schief, W.R, Wilson, I.A. | Deposit date: | 2016-07-24 | Release date: | 2016-08-10 | Last modified: | 2023-10-04 | Method: | X-RAY DIFFRACTION (3.25 Å) | Cite: | Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Plos Pathog., 12, 2016
|
|
5IDL
| Crystal structure of the germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT8 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, Germline-targeting HIV-1 gp120 engineered outer domain, eOD-GT8 | Authors: | Julien, J.P, Ereno-Orbea, J, Jardine, J.G, Schief, W.R, Wilson, I.A. | Deposit date: | 2016-02-24 | Release date: | 2016-10-05 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (2.9 Å) | Cite: | HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen. Science, 351, 2016
|
|
5D9Q
| Crystal Structure of the BG505 SOSIP gp140 HIV-1 Env trimer in Complex with the Broadly Neutralizing Fab PGT122 and scFv NIH45-46 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Envelope glycoprotein gp120, ... | Authors: | Julien, J.-P, Stanfield, R.L, Ward, A.B, Wilson, I.A. | Deposit date: | 2015-08-18 | Release date: | 2016-08-17 | Last modified: | 2023-09-27 | Method: | X-RAY DIFFRACTION (4.4 Å) | Cite: | Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design. Plos Pathog., 12, 2016
|
|
5IF0
| |
5IES
| |
5IFA
| |
8SXP
| |
4L8I
| Crystal structure of RSV epitope scaffold FFL_005 | Descriptor: | RSV epitope scaffold FFL_005 | Authors: | Jardine, J, Correnti, C, Holmes, M.A, Strong, R.K, Schief, W.R. | Deposit date: | 2013-06-17 | Release date: | 2014-02-12 | Last modified: | 2024-02-28 | Method: | X-RAY DIFFRACTION (2 Å) | Cite: | Proof of principle for epitope-focused vaccine design. Nature, 507, 2014
|
|
6XC4
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.3 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CC12.3 heavy chain, CC12.3 light chain, ... | Authors: | Yuan, M, Liu, H, Wu, N.C, Zhu, X, Wilson, I.A. | Deposit date: | 2020-06-08 | Release date: | 2020-07-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.341 Å) | Cite: | Structural basis of a shared antibody response to SARS-CoV-2. Science, 369, 2020
|
|
6XC3
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.1 and CR3022 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CC12.1 heavy chain, CC12.1 light chain, ... | Authors: | Yuan, M, Liu, H, Wu, N.C, Zhu, X, Wilson, I.A. | Deposit date: | 2020-06-08 | Release date: | 2020-07-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.698 Å) | Cite: | Structural basis of a shared antibody response to SARS-CoV-2. Science, 369, 2020
|
|
6XC7
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies CC12.3 and CR3022 | Descriptor: | CC12.3 heavy chain, CC12.3 light chain, CR3022 heavy chain, ... | Authors: | Yuan, M, Liu, H, Wu, N.C, Zhu, X, Wilson, I.A. | Deposit date: | 2020-06-08 | Release date: | 2020-07-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (2.883 Å) | Cite: | Structural basis of a shared antibody response to SARS-CoV-2. Science, 369, 2020
|
|
6XC2
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with neutralizing antibody CC12.1 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, CC12.1 heavy chain, CC12.1 light chain, ... | Authors: | Yuan, M, Liu, H, Wu, N.C, Zhu, X, Wilson, I.A. | Deposit date: | 2020-06-08 | Release date: | 2020-07-08 | Last modified: | 2023-10-18 | Method: | X-RAY DIFFRACTION (3.112 Å) | Cite: | Structural basis of a shared antibody response to SARS-CoV-2. Science, 369, 2020
|
|
8DGV
| |
8DGW
| |
8DGU
| |
8DGX
| |
8DT8
| LM18/Nb136 bispecific tetra-nanobody immunoglobulin in complex with SARS-CoV-2-6P-Mut7 S protein (focused refinement) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, LM18 nanobody, Nb136 nanobody, ... | Authors: | Ozorowski, G, Turner, H.L, Ward, A.B. | Deposit date: | 2022-07-25 | Release date: | 2023-06-14 | Method: | ELECTRON MICROSCOPY (3.34 Å) | Cite: | Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins. Proc.Natl.Acad.Sci.USA, 120, 2023
|
|
4N9G
| |
4JLR
| Crystal structure of a designed Respiratory Syncytial Virus Immunogen in complex with Motavizumab | Descriptor: | Motavizumab Fab heavy chain, Motavizumab Fab light chain, PENTAETHYLENE GLYCOL, ... | Authors: | Rupert, P.B, Correia, B, Schief, W, Strong, R.K. | Deposit date: | 2013-03-12 | Release date: | 2014-02-05 | Last modified: | 2014-12-17 | Method: | X-RAY DIFFRACTION (2.71 Å) | Cite: | Proof of principle for epitope-focused vaccine design. Nature, 507, 2014
|
|
8ELP
| |
8ELO
| |
8ELQ
| |
8GF2
| Crystal structure of SARS-CoV-2 receptor binding domain in complex with antibodies eCR3022.20 and CC12.3 | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, CC12.3 Fab heavy chain, ... | Authors: | Yuan, M, Zhu, X, Wilson, I.A. | Deposit date: | 2023-03-07 | Release date: | 2023-08-23 | Method: | X-RAY DIFFRACTION (2.851 Å) | Cite: | Broadening a SARS-CoV-1-neutralizing antibody for potent SARS-CoV-2 neutralization through directed evolution. Sci.Signal., 16, 2023
|
|
7RU1
| SARS-CoV-2-6P-Mut7 S protein (C3 symmetry) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Ozorowski, G, Turner, H.L, Ward, A.B. | Deposit date: | 2021-08-16 | Release date: | 2022-08-24 | Last modified: | 2024-01-17 | Method: | ELECTRON MICROSCOPY (2.8 Å) | Cite: | Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. Iscience, 25, 2022
|
|
7RU2
| SARS-CoV-2-6P-Mut7 S protein (asymmetric) | Descriptor: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Spike glycoprotein | Authors: | Ozorowski, G, Turner, H.L, Ward, A.B. | Deposit date: | 2021-08-16 | Release date: | 2022-08-24 | Last modified: | 2024-01-17 | Method: | ELECTRON MICROSCOPY (3 Å) | Cite: | Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways. Iscience, 25, 2022
|
|